Скачать с ютуб MANIFEST: pelabresib in combination with ruxolitinib in myelofibrosis в хорошем качестве

MANIFEST: pelabresib in combination with ruxolitinib in myelofibrosis

John Mascarenhas, MD, The Mount Sinai Hospital, New York, NY, discusses data from the MANIFEST study (NCT02158858), an open-label, Phase II study investigating the safety and efficacy of pelabresib in combination with ruxolitinib in patients with myelofibrosis (MF). In this video, Dr Mascarenhas discusses data from arms 2 and 3 of the study. In arm 2, patients with suboptimal response to ruxolitinib were treated with pelabresib as an add-on to ruxolitinib, and in arm 3, JAK inhibitor-naïve patients were treated with pelabresib in combination with ruxolitinib. The Phase II interim data showed that treatment was well-tolerated in both treatment arms and resulted in splenic and symptoms responses. Based on data from arm 3 of the Phase II study, a randomized, double-blind, active control, Phase III MANIFEST-2 study (NCT04603495) has been initiated. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.